Overview
The National Cancer Institute’s Office of Cancer Clinical Proteomics Research (OCCPR) and Clinical Proteomic Tumor Analysis Consortium (CPTAC) are pleased to announce the 2025 CPTAC Scientific Symposium. Join us on September 30, 2025 to learn about the most current advances in the field of cancer proteogenomics and cancer research by our CPTAC investigators. While this meeting is in-person for CPTAC consortium and NIH participants, only virtual option is available for public attendees.
The CPTAC program is a national effort to accelerate the understanding of cancer biology through the integration of large-scale proteome and genome analysis, or proteogenomics. The mission of the NCI’s OCCPR is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as CPTAC, partnerships with Federal agencies, and collaborations with other organizations/institutions.
Proteogenomics allows CPTAC researchers to illuminate tumor carcinogenesis and progression, microenvironments, and immune landscapes. This information may then be exploited therapeutically to improve patient care. CPTAC has pioneered the integrated proteogenomic analysis of multiple cancer types to reveal new insights into these cancer types, such as: identification of proteomic-centric subtypes, prioritization of driver mutations by correlative analysis of copy number alterations and protein abundance, and understanding cancer-relevant pathways through post-translational modifications.
We are excited to share our findings with you! We hope you can join us! Sign up for CPTAC email updates: https://proteomics.cancer.gov/sign-email-updates